Invest in the orthopedics of the future
Monogram is offering preferred Series-A shares in a Reg-A public offering. Learn more about how you can invest and support our technology here.
Join us in making this future a reality
Monogram is offering up to preferred series-A shares in this offering to help fund the development and commercialization of our implants, robotics and software.
as of today, we’ve raised
The minimum raise in this offering is $2,750,000. Management estimates the minimum amount required to reach FDA approval to be approximately $7 million.
For an overview of our development plan and strategic business initiatives please watch this quick 5-minute presentation here.
We anticipate being able to start delivering our surgical robots for insertion of generic implants within four years of the close of this offering, assuming no clinical data requests from the FDA.
Monogram’s first target markets will be the hip and knee replacement market which is over $18bn combined.
THE MAJORITY OF THE MARKET IS IMPLANT SALES, WHICH IS WHY MONOGRAM HAS FOCUSED ON INNOVATING THE IMPLANT.
After investing over $225M in 3D printing Styker indicated 100% of their hip cups will be 3D printed. This is getting more efficient than conventional manufacturing. Monogram is developing implants for this future.
“ADDITIVE MANUFACTURING IS THE FUTURE.” KEVIN LOBO, STRYKER CEO
51% of primary hip and knee joint replacement surgeries will be performed in an outpatient setting by 2026. The industry is rapidly shifting to force efficiency on large suppliers. Monogram is built on efficiency.
WE DO NOT BELIEVE HIGH VOLUME HOSPITALS WITH INVENTORY ON CONSIGNMENT IS THE FUTURE
The average implant sits on the shelf for 9.7 months before getting sold. This inefficiency costs the large companies billions of dollars in
Saves $3,000 per surgery on average by reducing the amount of inventory you need on hand.